Search clinical trials for: Capecitabine, camrelizumab

Total 2243 results

Fudan University

Recruiting

Fluzoparib and Camrelizumab in Treating Patients With R/M NPC That Progressed After First-line Chemotherapy

Nasopharyngeal Carcinoma | Nasopharyngeal Cancer

China
The Second Affiliated Hospital of Fujian Medical...

Active, not recruiting

Efficacy and Safety of SOX Regimen Combined With Camrelizumab as Neoadjuvant Treatment in Locally Advanced Gastric Cancer: a Phase II, Single-arm Study

Digestive System Diseases | Neoplasms | Neoplasms by Site | Stomach Neoplasms | Digestive System Neoplasms | Stomach Diseases

China
Chinese PLA General Hospital

Recruiting

The Clinical Trial of Chidamide+Decitabine+Camrelizumab Versus Decitabine+Camrelizumab in Anti-PD-1 Antibody Resistant Patients With Classical Hodgkin Lymphoma.

Hodgkin Lymphoma | Anti-PD-1 Antibody Resistant

China
Zhejiang Cancer Hospital
Zhejiang Provincial People's Hospital; Jinhua Municipal Central Hospital; Huizhou... and other collaborators

Not yet recruiting

A Multicenter, Randomized Controlled, Phase II Clinical Study of First-line Chemotherapy and Camrelizumab With or Without Radiotherapy in the Treatment of Oligometastatic Esophageal Cancer

Esophageal Cancer

China
Eye & ENT Hospital of Fudan University
Chinese Academy of Medical Sciences

Recruiting

Camrelizumab and Chemotherapy Combined With Endoscopic Surgery for Recurrent Nasopharyngeal Carcinoma

Recurrent Nasopharyngeal Carcinoma

China
Hospital of Stomatology, Wuhan University
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

Neoadjuvant PD-1 Blockade in Resectable Oral Squamous Cell Carcinoma (NEOPBOSCC)

Oral Squamous Cell Carcinoma

China
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

A Single-arm Phase II Clinical Study of the Efficacy and Safety of Camrelizumab Combined With GEMOX for Unresectable GBCs

Unresectable Gallbladder Cancer

China
Wuhan Union Hospital, China

Recruiting

The Efficacy and Safety of TACE, Lenvatinib and Camrelizumab in the Treatment of BCLC Stage B/C Hepatocellular Carcinoma: a Single-arm, Single-center, Open-label Study

Hepatocellular Carcinoma

China
Fudan University
Shanghai Shen Kang Hospital Development Center

Recruiting

Safety and Efficacy of Camrelizumab for High-risk NMIBC Failing BCG Treatment

Urinary Bladder Neoplasms | Immunotherapy

China
The First Affiliated Hospital of Zhengzhou University

Not yet recruiting

Study of First-line Camrelizumab With or Without Chemotherapy for Advanced Esophageal Squamous Cell Cancer

Esophageal Cancer

China
Tianjin Medical University Cancer Institute and...
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

Conversion Therapy of Camrelizumab Plus Chemoradiotherapy in Participants With Initial Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

Gastric Cancer
Sun Yat-sen University

Active, not recruiting

PD-1 Antibody Versus Best Supportive Care After Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma (DIPPER)

Nasopharyngeal Neoplasms

China
Shanghai Minimally Invasive Surgery Center

Suspended

A Pilot Study of Neoadjuvant Chemotherapy With or Without Camrelizumab for Locally Advanced Gastric Cancer

Gastric Cancer

China
Henan Cancer Hospital

Recruiting

Camrelizumab Combined With Cisplatin in the Treatment of Advanced Cutaneous Squamous Cell Carcinoma

Squamous Cell Carcinoma of the Skin

China
Lei Li

Recruiting

PD-1 Antibody Plus Chemoradiotherapy for IB2-IIIB Cervical Cancer

Cervical Carcinoma | Immunotherapy | Survival Outcomes | Adverse Events | Locally Advanced Cervical Cancer | Chemoradiotherapy | Immune Checkpoint Inhibitor | Anti-programmed Cell Death Receptor 1 | Early Stage Cervical Cancer

China
Peking Union Medical College Hospital
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Camrelizumab Plus Apatinib in Patients With High-risk Gestational Trophoblastic Neoplasia

Gestational Trophoblastic Neoplasia

China
Sun Yat-sen University
Chengdu Biostar Pharmaceuticals

Not yet recruiting

Utidelone Plus Capecitabine Versus Taxane Plus Capecitabine in HER2-negative Locally Advanced or Metastatic Breast Cancer

Breast Neoplasms | Locally Advanced or Metastatic Breast Cancer

China
Fudan University

Recruiting

Anti-PD-1 Antibody in the Treatment of Patients With Malignant Melanoma of the Female Genital Tract

Malignant Melanoma

China
The First Affiliated Hospital with Nanjing Medical...
Jiangsu HengRui Medicine Co., Ltd.

Completed

Microwave Ablation Combined With Camrelizumab in the Treatment of Early Breast Cancer

Breast Cancer

China
Peking University
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Study of Camrelizumab (SHR-1210) and Apatinb Based Therapies for Alpha-fetoprotein (AFP)-Producing Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

Gastric Cancer

China
Yue Han
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

HAIC Combined With Camrelizumab and TKI for Unresectable Hepatocellular Carcinoma After TACE Failure

Unresectable Hepatocellular Carcinoma

China
Hoffmann-La Roche

Completed

A Study of Capecitabine Rapid Disintegrating Tablets (RDT) Versus Commercial Xeloda in Patients With Solid Tumours

Breast Cancer, Colorectal Cancer

New Zealand, Australia, United Kingdom
Hunan Cancer Hospital
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Study of Camrelizumab Combined With Concurrent Chemoradiation in Patients With Cervical Cancer

Cervical Cancer

China
Fudan University

Recruiting

Cryoablation Combined With Anti-PD-1 Antibody in Patients With Advanced Intrahepatic Cholangiocarcinoma

Intrahepatic Cholangiocarcinoma

China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Enrolling by invitation

A Trial of SHR-2002 Injection or Combined With Other Anti-cancer Medication in Advanced Malignant Tumors of Patients

Advanced Malignant Tumors

China
Sun Yat-sen University
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Neoadjuvant Camrelizumab in Combination With Cisplatin and Nab-paclitaxel in Resectable HNSCC

Head and Neck Squamous Cell Carcinoma

China
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological Tumors

Renal Cell Carcinoma | Cervical Cancer | Endometrial Cancer | Urothelial Carcinoma | Ovarian Cancer Recurrent

China
Shanghai Pulmonary Hospital, Shanghai, China

Recruiting

Efficiency and Safety of Microwave Ablation Plus Immune Checkpoint Inhibitor for Patients With Multiple Primary Lung Cancer: A Open, Multi-center, Phase II Clinical Trial (MAGIC)

Multiple Primary Lung Cancer

China
Binghe Xu
Hoffmann-La Roche

Unknown

Capecitabine Maintenance Therapy Following Capecitabine Combined With Docetaxel in Treatment of mBC (CAMELLIA)

Skin Diseases | Neoplasms by Site | Breast Neoplasms | Breast Diseases | Neoplasm Metastasis

China
Fudan University

Recruiting

A Trial Exploring the Opportune Administration of Nab-paclitaxel in the First Line Treatment, Camrelizumab Combined With Nab-paclitaxel and Famitinib, of TNBC.

Triple-Negative Breast Cancer

China
Wuhan Union Hospital, China
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

Short-Course Radiotherapy Followed by Neoadjuvant Chemotherapy and Camrelizumab in Locally Advanced Rectal Cancer (UNION)

Rectal Cancer

China
Cyclacel Pharmaceuticals, Inc.

Completed

Efficacy Study of Oral Sapacitabine to Treat Acute Myeloid Leukemia in Elderly Patients

Acute Myeloid Leukemia

United States
Shanghai Zhongshan Hospital

Enrolling by invitation

Study of TACE Combined With Camrelizumab in the Treatment of HCC Patients

Hepatocellular Carcinoma

China
Jules Bordet Institute

Completed

Adjuvant Capecitabine in Elderly Patients With Breast Cancer: a Phase II Study

Breast Cancer | Elderly Patients

Belgium
Samsung Medical Center

Completed

Phase II Trial of XP Versus XG in Advanced Esophageal Squamous Cell Carcinoma

Advanced or Recurrent Esophageal Squamous Cell Carcinoma

Korea, Republic of
Fudan University

Completed

Capecitabine and Pseudomonas Aeruginosa Combination in Metastatic Breast Cancer (MBC)

Metastatic Breast Cancer

China
Sichuan Cancer Hospital and Research Institute

Recruiting

Camrelizumab Combination With SBRT and Concurrent Chemotherapy Treated Stage IV Oligometastatic Non-small Cell Lung Cancer (IMCORT-2)

Non-small Cell Lung Cancer Metastatic

China
Chinese PLA General Hospital

Not yet recruiting

Efficacy and Safety of Perioperative Chemotherapy Plus PD-1 Antibody in Gastric Cancer

Gastric Cancer

China
Hunan Cancer Hospital
Jiangsu HengRui Medicine Co., Ltd.

Not yet recruiting

A Study of Carilizumab Combined With Concurrent Chemoradiotherapy

Cervical Cancer
Cancer Institute and Hospital, Chinese Academy...
Hoffmann-La Roche

Unknown

Capecitabine (NX) Versus Docetaxel Plus Capecitabine (TX) as 1-line Chemotherapy on Metastatic Breast Cancer (MBC)

Carcinoma, Invasive Ductal, Breast

China
The First Affiliated Hospital of Zhengzhou University

Recruiting

Duration of Adjuvant Chemotherapy for Gastric Cancer Patients at Pathological N3 Stage

Gastric Cancer

China
Jiangxi Provincial Cancer Hospital

Recruiting

Maintenance Therapy With Toripalimab and Capecitabine Versus Capecitabine Alone in High-risk Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma | Maintenance Therapy | High-Risk Cancer

China
Hebei Medical University

Completed

Preoperative Concurrent Chemoradiotherapy for Potentially Resectable Adenocarcinoma of the Esophagogastric Junction (A-C)

Gastroesophageal Junction Adenocarcinoma

China
Beijing Chao Yang Hospital

Recruiting

Camrelizumab Combined With Neoadjuvant Chemotherapy After Stent Placement for Left-Sided Obstructive Colonic Cancer (NACSOC-02)

Colorectal Cancer | Obstruction | Immunotherapy | Neoadjuvant Chemotherapy | Stent

China
Chongqing University Cancer Hospital

Recruiting

The Efficacy of Camrelizumab Plus Stereotactic Body Radiotherapy in R/M NPC

Nasopharyngeal Carcinoma

China
Fudan University

Unknown

PD-1 Antibody Combined With Modified FLOT Regimen in the Treatment of Unresectable Locally Advanced or Limited Metastatic Gastric Cancer

Metastatic Gastric Cancer | Locally Advanced Gastric Adenocarcinoma

China
Peking University

Not yet recruiting

The Neoadjuvant Treatment of Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma

Thoracic Esophageal Squamous Cell Carcinoma

China
Sun Yat-sen University
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Trial of Hepatic Arterial Infusion Combined With Apatinib and Camrelizumab Versus Apatinib and Camrelizumab for C-staged Hepatocellular Carcinoma in BCLC Classification (TRIPLET-III)

C-staged Hepatocellular Carcinoma in BCLC Classification

China
University of Southern California
National Cancer Institute (NCI)

Recruiting

A Dose Finding Phase 1 of Sarilumab Plus Capecitabine in HER2/Neu-Negative Metastatic Breast Cancer and a Single-arm, Historically-controlled Phase 2 Study of Sarilumab Plus Capecitabine in Stage I-III Triple Negative Breast Cancer With High-Risk Residual Disease (EMPOWER) (EMPOWER)

Cancer | Metastatic | Breast | Triple Negative | Disseminated Tumor Cell

United States
Huazhong University of Science and Technology

Unknown

Evaluate the Efficacy of Maintenance Treatment With Capecitabine Plus Apatinib in Advanced Gastric Cancer

Gastric Cancer

China

3

Subscribe